533 related articles for article (PubMed ID: 20298209)
1. Synaptic dysfunction in Parkinson's disease.
Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
[TBL] [Abstract][Full Text] [Related]
2. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
3. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.
Picconi B; Pisani A; Barone I; Bonsi P; Centonze D; Bernardi G; Calabresi P
Neurotoxicology; 2005 Oct; 26(5):779-83. PubMed ID: 15927256
[TBL] [Abstract][Full Text] [Related]
4. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
5. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
6. Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits.
Calabresi P; Galletti F; Saggese E; Ghiglieri V; Picconi B
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S259-62. PubMed ID: 18267247
[TBL] [Abstract][Full Text] [Related]
7. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
Picconi B; Ghiglieri V; Bagetta V; Barone I; Sgobio C; Calabresi P
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S145-9. PubMed ID: 18583173
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Calabresi P; Giacomini P; Centonze D; Bernardi G
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
[TBL] [Abstract][Full Text] [Related]
9. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
10. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
[TBL] [Abstract][Full Text] [Related]
11. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
14. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
Cenci MA; Lundblad M
J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
[TBL] [Abstract][Full Text] [Related]
15. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
[TBL] [Abstract][Full Text] [Related]
16. MPTP-meditated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity.
Zhu G; Chen Y; Huang Y; Li Q; Behnisch T
Toxicol Appl Pharmacol; 2011 Aug; 254(3):332-41. PubMed ID: 21605582
[TBL] [Abstract][Full Text] [Related]
17. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
19. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Oh JD; Chase TN
Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of l-DOPA-induced dyskinesia.
Fisone G; Bezard E
Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
